Navigation Links
AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
Date:9/21/2009

ting GI problems, no clinically relevant drug-related adverse events or changes in laboratory safety parameters were observed.

"Prolonged courses of stable disease with minimal to no toxicity are encouraging signs", said Dr. Von Hoff. "The applications for an oral agent with these mechanisms of action are numerous."

Paul Blake, MD, AEterna Zentaris Senior Vice President and Chief Medical Officer added, "We are pleased with these Phase 1 results on AEZS-112, which indicate the potential for safe combination with other anticancer drugs. We now look forward to working on the further development of AEZS-112 in collaboration with our expert investigators."

About the AEZS-112 Phase 1 Study

This open-label, dose-escalation, multi-center, intermittent treatment Phase 1 study included patients with advanced solid tumors and lymphoma who had either failed standard therapy or for whom no standard therapy existed. Patients received a once-a-week oral administration of AEZS-112 for three consecutive weeks, followed by a one-week period without treatment. The cycles were repeated every four weeks based on tolerability and response, basically planned for up to four cycles, but allowing for continuation in case of potential benefit for the patient. The starting dose of AEZS-112 in this study was 13 mg/week, with doubling of doses in subsequent cohorts in the absence of significant toxicity. Primary endpoints of the Phase 1 trial focused on determining the safety and tolerability of AEZS-112 (maximum tolerated dose, MTD), as well as establishing a recommended Phase 2 dose and regimen. Secondary endpoints aimed at establishing the pharmacokinetics and determining the efficacy based on standard response criteria.

Preliminary results from this study were presented recently at the American Association for Cancer Research (AACR) Annual Meeting in Denver, Colorado. Poster #5567 entitled, "Phase I dose-escalation, safety, and pharma
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
2. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
3. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
5. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
6. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
7. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
8. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
9. AEterna Zentaris Receives US$10 Million from Institutional Investors
10. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
11. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Labs, Inc. (OTC Bulletin Board: GOVX ), a ... today announced the results of its Annual Shareholders Meeting, held ... re-elected seven nominees for directors of the company to serve ... successors are duly elected or appointed and qualified. They are: ...
... Inc., (OTC Bulletin Board: BHRT ) announces ... stem cell therapy on the first two congestive heart ... Tijuana through its Center of Excellence, Regenerative Medicine Institute ... agreement to establish a Center of Excellence for the ...
... 26 Verenium Corporation (Nasdaq: VRNM ... of high-performance industrial enzyme solutions, today announced the ... Vice President of Manufacturing. Bracken will report to ... Verenium,s Enzymes Business. "Kevin brings over ...
Cached Biology Technology:GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 2GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 3GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 4Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program 2Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program 3Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program 4Verenium Appoints Kevin Bracken Vice President of Manufacturing 2Verenium Appoints Kevin Bracken Vice President of Manufacturing 3
(Date:4/24/2014)... they often inject harmful proteins into the host ... However, in some plants, bacteria attack once they,ve ... Now, researchers at the University of Missouri have ... bacteriaknown mostly for attacking tomatoesto invade its host. ... that work with food-producing plants to enhance resistance ...
(Date:4/24/2014)... Rochelle, NY, April 24, 2014GEN Publishing recently introduced ... digital publication focusing on the application of OMICs ... as next-gen sequencing, are beginning to transform medical ... research over the past decade-and-a-half. , "GEN,s editors ... of pharmacogenomics, genomics, metabolomics, transcriptomics, etc. etc. for ...
(Date:4/24/2014)... New Rochelle, NY, April 24, 2014D-ribose is a ... nutritional supplement, and as a starting compound for ... of Escherichia coli to increase the ... step toward achieving more efficient industrial-scale production of ... in Industrial Biotechnology , a peer-reviewed journal ...
Breaking Biology News(10 mins):Plants send out signals attracting harmful bacteria, MU study finds 2
... LUMPUR, Malaysia, Oct. 17, 2012 Rising crime ... governments to increase monitoring and introduce reliable border ... aimed at criminal identification and automated immigration at ... drive biometrics adoption in the government vertical across ...
... 2012  Aware, Inc. (NASDAQ: AWRE ), a ... products, today reported financial results for its third quarter ... DSL service assurance hardware business have been reported as ... shutdown of that business during the third quarter. Accordingly, ...
... Adm. Matthew Klunder, the chief of naval research, told a ... and technology (S&T) conference this week that he intends to ... together on a quarterly basis, starting in 2013, to accelerate ... every two years, which is phenomenal and very valuableand probably ...
Cached Biology News:Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 2Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 3Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 4Aware, Inc. Reports Third Quarter 2012 Financial Results 2Aware, Inc. Reports Third Quarter 2012 Financial Results 3Aware, Inc. Reports Third Quarter 2012 Financial Results 4Aware, Inc. Reports Third Quarter 2012 Financial Results 5Aware, Inc. Reports Third Quarter 2012 Financial Results 6In an uncertain world, Navy needs science and technology collaboration, chief says 2
... Mouse C2C12 cells were cultured in DMEM and ... In order to keep the antigens in their ... The cells are arrayed on a 12-well (5 ... specifically treated to enhance cellular attachment and to ...
... Sample Buffer is a convenient, ... experimental samples and Perfect RNA ... needs no dilution and is ... gels. Simply mix equal volumes ...
... cells were cultured in DMEM and harvested at ... to keep the antigens in their native forms, ... are arrayed on a 12-well (5 mm) adhesive ... to enhance cellular attachment and to minimize background ...
... CopyControl™ vector can be induced prior to ... provide the stability of single-copy BACs with ... other cloning vectors. The kits provide the ... insert size screening system) necessary to create ...
Biology Products: